NTRK2 Gene
Introduction
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">NTRK2 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>NTRK2</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Neurotrophic Receptor Tyrosine Kinase 2</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>9q22.1</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>4915</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000148018</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q16620</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>600456</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Status</td>
</tr>
<tr>
<td class="label">BDNF mimetics</td>
<td>Research</td>
</tr>
<tr>
<td class="label">TrkB agonists</td>
<td>Clinical trials</td>
</tr>
<tr>
<td class="label">TrkB modulators</td>
<td>Research</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Exercise therapy</td>
<td>Proven</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NCT01703091</td>
<td>Phase I/II</td>
</tr>
<tr>
<td class="label">NCT02145628</td>
<td>Phase I</td>
</tr>
<tr>
<td class="label">NCT05343728</td>
<td>Phase I</td>
</tr>
<tr>
<td class="label">NCT05552369</td>
<td>Phase II</td>
</tr>
<tr>
<td class="label">NCT04833161</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">SNP</td>
<td>Location</td>
</tr>
<tr>
<td class="label">rs6265</td>
<td>Val66Met</td>
</tr>
<tr>
<td class="label">rs2289656</td>
<td>Promoter</td>
</tr>
<tr>
<td class="label">rs1867283</td>
<td>Intron</td>
</tr>
<tr>
<td class="label">rs1659412</td>
<td>3'UTR</td>
</tr>
<tr>
<td class="label">Model</td>
<td>Advantages</td>
</tr>
<tr>
<td class="label">Knockout mice</td>
<td>Complete gene loss</td>
</tr>
<tr>
<td class="label">Conditional KO</td>
<td>Tissue-specific</td>
</tr>
<tr>
<td class="label">Transgenic</td>
<td>overexpression</td>
</tr>
<tr>
<td class="label">iPSC neurons</td>
<td>Human context</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">Alzheimer's disease</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/carcinoma" style="color:#ef9a9a">Carcinoma</a>, <a href="/wiki/glioblastoma" style="color:#ef9a9a">Glioblastoma</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">77 edges</a></td>
</tr>
</table>
Ntrk2 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
NTRK2 (Neurotrophic Receptor Tyrosine Kinase 2) encodes the BDNF (brain-derived neurotrophic factor) receptor, also known as TrkB. This receptor tyrosine kinase is essential for synaptic plasticity, learning, memory, and neuronal survival. NTRK2 is a major therapeutic target for depression, Alzheimer's disease, and neurodegenerative disorders.
Protein Structure and Mechanism
Receptor Architecture
TrkB is a transmembrane receptor tyrosine kinase with distinct structural domains[@huang2001]:
- Extracellular domain: Contains leucine-rich repeats (LRR) and immunoglobulin-like domains for ligand binding
- Transmembrane domain: Single pass helix anchoring the receptor in the lipid bilayer
- Cytoplasmic domain: Tyrosine kinase domain that phosphorylates downstream signaling proteins
Activation Mechanism
BDNF binding triggers TrkB dimerization and autophosphorylation:
BDNF binds to the extracellular domain, inducing receptor dimerization
Kinase domain activation leads to autophosphorylation of tyrosine residues
Phosphotyrosine residues serve as docking sites for downstream signaling proteins
Activation of PI3K/Akt, MAPK/ERK, and PLCγ pathways
- TrkB.FL (full-length): Contains the tyrosine kinase domain, mediates all known TrkB signaling
- TrkB.T1: Truncated isoform lacking the kinase domain, may act as a dominant-negative regulator
- TrkB.T2: Another truncated variant with distinct tissue distribution
Normal Function
- BDNF receptor: High-affinity binding to BDNF and NT-4/5
- Synaptic plasticity: [Long-term potentiation](/mechanisms/long-term-potentiation) (LTP), dendritic spine formation
- Learning and memory: Critical for [hippocampus](/brain-regions/hippocampus)-dependent memory
- Neuronal survival: Activates PI3K/Akt, MAPK/ERK, and PLCγ pathways
- Axonal guidance: Role in development and regeneration
Signaling Pathways
TrkB activates three major downstream signaling cascades upon BDNF binding:
Mermaid diagram (expand to render)
PI3K/Akt Pathway
The PI3K/Akt pathway is the primary pro-survival signaling cascade activated by TrkB[@huang2001]:
- Activation of Akt promotes cell survival through phosphorylation of Bad
- mTOR activation leads to protein synthesis and synaptic plasticity
- Akt also inhibits glycogen synthase kinase-3 beta (GSK3β), reducing tau phosphorylation
MAPK/ERK Pathway
The Ras/MEK/ERK pathway regulates[@minichiello2009]:
- Neuronal differentiation during development
- Synaptic plasticity and LTP formation
- Activity-dependent gene expression
PLCγ Pathway
Phospholipase C-gamma (PLCγ) activation leads to[@poo2001]:
- Increased intracellular calcium
- Activation of PKC isoforms
- Modulation of synaptic transmission
Disease Associations
Alzheimer's Disease
BDNF/TrkB signaling is critically impaired in Alzheimer's disease[@allen2013][@zhou2016]:
- Synaptic loss: BDNF/TrkB signaling is essential for synaptic plasticity, and reduced TrkB expression in AD hippocampus contributes to synaptic dysfunction
- Amyloid interaction: Amyloid-beta oligomers disrupt BDNF signaling, creating a vicious cycle of neurodegeneration
- Tau phosphorylation: Impaired TrkB signaling leads to dysregulated GSK3β activity, increasing tau pathology
- Cognitive decline: Reduced TrkB activation correlates with cognitive decline in AD patients
Therapeutic strategies:
- AAV-mediated BDNF delivery to restore TrkB signaling[@liu2015]
- Small molecule TrkB agonists and BDNF mimetics[@bishop2010]
- Exercise and environmental enrichment to increase endogenous BDNF
Parkinson's Disease
BDNF supports dopaminergic neuron survival through NTRK2 signaling[@twardziok2019]:
- Dopaminergic protection: TrkB activation protects substantia nigra pars compacta neurons from degeneration
- Axonal maintenance: BDNF/TrkB signaling maintains dopaminergic terminals in the striatum
- α-synuclein interaction: TrkB signaling can protect neurons from α-synuclein toxicity
- Therapeutic approaches: AAV-BDNF/TrkB gene therapy approaches being investigated
Depression and Anxiety
The BDNF/TrkB pathway is a key mediator of antidepressant efficacy[@saarelainen2000][@autry2012]:
- Antidepressant action: Most antidepressant treatments increase BDNF expression and TrkB signaling
- Rapid-acting antidepressants: Ketamine's rapid antidepressant effects are mediated through TrkB activation
- Genetic variants: NTRK2 polymorphisms associated with treatment response and depression risk
Other Diseases
- Rett syndrome: NTRK2 dysregulation contributes to neurological deficits
- Huntington's Disease: BDNF/TrkB signaling deficit contributes to striatal neuron degeneration
- Epilepsy: Altered TrkB expression in epileptic tissue
- Various psychiatric disorders: TrkB signaling alterations in depression, anxiety, and PTSD
Expression
Brain Region Distribution
TrkB exhibits region-specific expression throughout the brain[@huang2001]:
- Hippocampus: High expression in CA1-CA3 pyramidal neurons and dentate gyrus granule cells
- Cortex: Strong expression in layers II-III and V pyramidal neurons
- Basal ganglia: Moderate expression in striatum and substantia nigra pars compacta
- Cerebellum: Expression in Purkinje cells and granule cells
- Amygdala: Variable expression depending on subnucleus
Cellular Expression
TrkB is expressed in multiple cell types[@carvajal2008]:
- Neurons: Pyramidal neurons, GABAergic interneurons, dopaminergic neurons
- Astrocytes: Moderate TrkB expression, may participate in astrocyte-neuron signaling
- Microglia: Low-level expression, BDNF may modulate microglial activity
- Oligodendrocytes: Expression in mature oligodendrocytes, supports myelination
Subcellular Localization
- Synaptic membranes: Highest density at postsynaptic densities
- Dendritic compartments: Concentrated in dendritic shafts and spines
- Endosomes: TrkB internalization and recycling through endosomal compartments
- Nucleus: Some evidence for nuclear TrkB signaling
Therapeutic Targeting
Cellular and Circuit-Level Effects
Synaptic Plasticity
TrkB signaling is essential for multiple forms of synaptic plasticity[@carvajal2008]:
- Long-term potentiation (LTP): BDNF/TrkB signaling is required for LTP induction in the hippocampus
- Dendritic spine formation: TrkB activation promotes the growth and maintenance of dendritic spines
- Synaptic vesicle trafficking: TrkB signaling modulates presynaptic release probability
- Homeostatic plasticity: TrkB mediates activity-dependent synaptic scaling
Neuronal Survival Mechanisms
The PI3K/Akt pathway activated by TrkB promotes neuronal survival through:
- Bad phosphorylation: Akt phosphorylates Bad, preventing it from inducing apoptosis
- Bcl-2 upregulation: TrkB signaling increases expression of anti-apoptotic Bcl-2 proteins
- Caspase inhibition: Akt activity inhibits caspase-9 and caspase-3 activation
- mTOR activation: Promotes protein synthesis required for neuronal health
Neurogenesis
TrkB signaling supports hippocampal neurogenesis:
- Neural progenitor cell survival: BDNF promotes proliferation and differentiation
- Dendritic development: TrkB signaling guides neuronal morphology
- Integration: Supports functional integration of new neurons into hippocampal circuits
TrkB Agonists in Development
Several TrkB-targeting therapeutics are in development[@kumar2020]:
- 7,8-Dihydroxyflavone (7,8-DHF): A small molecule TrkB agonist that crosses the blood-brain barrier
- Tropomyosin receptor kinase B agonists: Various pharmaceutical companies developing oral TrkB activators
- AAV2-BDNF: Gene therapy delivering BDNF to specific brain regions
- TrkB-directed antibodies: Agonist antibodies targeting TrkB
Clinical Trials
- NCT01703091: Brain-derived neurotrophic factor (BDNF) for Alzheimer's disease
- NCT02145628: AAV-BDNF for Parkinson's disease
- Various trials investigating TrkB modulators for depression and anxiety
Genetic Variants
Common Polymorphisms
The NTRK2 gene has several common polymorphisms that may affect disease risk:
- Val66Met (rs6265): Located in the BDNF coding region, affects activity-dependent BDNF secretion
- NTRK2 variants: Various promoter and coding variants associated with neurological phenotypes
Disease-Associated Mutations
Rare NTRK2 mutations have been linked to:
- Hyperphagic syndrome: Early-onset obesity
- Neurodevelopmental disorders: Developmental delay, intellectual disability
- Psychiatric conditions: Increased susceptibility to depression and anxiety
Future Research Directions
Emerging Therapeutic Approaches
Research continues to advance TrkB-based therapeutics:
- Phosphoramidate prodrugs: Novel BDNF mimetics with improved brain penetration
- Allosteric modulators: Positive allosteric modulators that enhance BDNF/TrkB signaling without direct receptor activation
- Cell-specific targeting: AAV vectors with neuron-specific promoters for targeted BDNF expression
- Combination therapies: BDNF/TrkB targeting combined with amyloid or tau-targeted approaches
Biomarker Development
Biomarkers for TrkB pathway activity include:
- BDNF levels: Peripheral BDNF as a proxy for central nervous system activity
- Phospho-TrkB: Direct measurement of activated TrkB in cerebrospinal fluid
- Transcriptional markers: Downstream gene expression signatures
Circuit-Specific Effects
Understanding how TrkB signaling differentially affects specific neural circuits:
- Hippocampal circuits: Memory formation and pattern separation
- Cortical circuits: Sensory processing and integration
- Basal ganglia circuits: Motor learning and habit formation
- Limbic circuits: Emotional regulation and mood
Clinical Trials and Therapeutic Development
Active and Recent Clinical Trials
Therapeutic Approaches
Small Molecule Agonists:
- 7,8-Dihydroxyflavone (7,8-DHF): First-in-class TrkB agonist that crosses the BBB
- Tropomyosin receptor kinase B agonists: Pharmaceutical development ongoing
- R13 and related compounds: Phosphoramidate prodrugs of BDNF
Gene Therapy:
- AAV2-BDNF: Adeno-associated virus-mediated BDNF delivery
- AAV-TrkB: Direct TrkB overexpression
- Lenti-BDNF: Lentiviral approaches for sustained expression
Biologic Approaches:
- TrkB agonist antibodies: Monoclonal antibodies activating TrkB
- BDNF mimetics: Engineered protein constructs
- Cell therapy: Stem cell-based BDNF delivery
Challenges and Solutions
Short half-life of BDNF: Addressed through viral vectors and stabilized proteins
Blood-brain barrier: AAV delivery and small molecule approaches
Peripheral toxicity: Targeted CNS delivery with AAV vectors
Dosage optimization: Biomarker-guided dosing strategiesMechanism of Action in Neurodegeneration
Synaptic Protection
TrkB signaling protects synapses through multiple mechanisms:
Mermaid diagram (expand to render)
Axonal Maintenance
TrkB supports axonal health through:
- Cytoskeletal stabilization: Regulation of tubulin and actin dynamics
- Axonal transport: Enhancement of molecular motor function
- Myelin maintenance: Support of oligodendrocyte function
Genetic Factors
NTRK2 Polymorphisms
Rare Mutations
- De novo mutations: Associated with developmental disorders
- Loss-of-function: Reduced TrkB signaling
- Gain-of-function: Constitutive activation
Biomarkers and Diagnostics
Fluid Biomarkers
- Serum BDNF: Peripheral marker, correlates with CNS activity
- CSF BDNF: Direct CNS measurement
- Phospho-TrkB: Activated receptor detection
- TrkB ectodomain: Soluble receptor fragment
Imaging Biomarkers
- PET tracers: TrkB visualization in development
- MRI: Functional connectivity changes
- SPECT: Receptor density mapping
Clinical Assessments
- Cognitive testing: MMSE, MoCA for AD
- Motor scoring: UPDRS for PD
- Mood assessments: Depression rating scales
Comparative Biology
Species Conservation
- Rodent TrkB: High conservation with human (>95%)
- zebrafish models: Developmental studies
- Non-human primates: Preclinical validation
Model Systems
Future Directions
Emerging Research Areas
Combination therapies: TrkB activation with amyloid/tau targeting
Precision medicine: Genetic stratification for treatment response
Biomarker-driven trials: Patient enrichment strategies
Novel delivery methods: Exosomes, focused ultrasoundUnmet Needs
- Efficient BBB penetration: Critical challenge
- Sustained activation: Long-term dosing issues
- Biomarker development: Patient selection
- Disease modification: Demonstrating slowing of progression
References
[Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function (2001)](https://pubmed.ncbi.nlm.nih.gov/11747827/). Annu Rev Neurosci. 2001;24:677-736.
[Poo MM. Neurotrophins as synaptic modulators (2001)](https://pubmed.ncbi.nlm.nih.gov/11212157/). Nat Rev Neurosci. 2001;2(1):24-32.
[Lu B, et al. BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases (2013)](https://pubmed.ncbi.nlm.nih.gov/23685773/). Nat Rev Neurosci. 2013;14(6):401-416.
[Autry AE, Monteggia LM. Brain-derived neurotrophic factor and neuropsychiatric disorders (2012)](https://pubmed.ncbi.nlm.nih.gov/22441914/). Pharmacol Rev. 2012;64(2):238-258.
[Murer MG, et al. Brain-derived neurotrophic factor in neurodegenerative diseases (2001)](https://pubmed.ncbi.nlm.nih.gov/11516551/). J Neurol Sci. 2001;191(1-2):21-24.
[Minichiello L. TrkB signalling mechanisms in the brain (2009)](https://pubmed.ncbi.nlm.nih.gov/19686687/). Nat Rev Neurosci. 2009;10(12):850-860.
[Carvajal A, et al. TrkB in the development and plasticity of the mammalian brain (2008)](https://pubmed.ncbi.nlm.nih.gov/18271038/). J Neurosci Res. 2008;86(6):1294-1308.
[Zhou F, et al. BDNF/TrkB signaling-mediated neuroprotection in Alzheimer's disease (2016)](https://pubmed.ncbi.nlm.nih.gov/27384040/). CNS Neurol Disord Drug Targets. 2016;15(8):1081-1088.
[Kumar A, et al. Targeting neurotrophin receptors in the aging brain (2020)](https://pubmed.ncbi.nlm.nih.gov/32842523/). Pharmaceuticals. 2020;13(9):260.
[Saarelainen T, et al. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs (2000)](https://pubmed.ncbi.nlm.nih.gov/11077147/). Neuropharmacology. 2000;39(10):1828-1836.
[Twardziok O, et al. Effectiveness of brain-derived neurotrophic factor in animal models of Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30570768/). J Neural Transm. 2019;126(1):87-100.
[Allen SJ, et al. BDNF: a key therapeutic target for Alzheimer's disease (2013)](https://pubmed.ncbi.nlm.nih.gov/23296339/). Nat Rev Neurol. 2013;9(3):131-134.
[Coultas L, et al. TrkB: a novel therapeutic target in neurodegenerative disease (2010)](https://pubmed.ncbi.nlm.nih.gov/20394745/). Exp Neurol. 2010;223(1):94-98.
[Bishop GM, et al. TrkB receptor agonists as potential disease-modifying therapies for Alzheimer's disease (2010)](https://pubmed.ncbi.nlm.nih.gov/20176148/). Neurodegener Dis. 2010;7(1-3):132-138.
[Liu Y, et al. AAV-mediated BDNF expression improves cognitive deficits in Alzheimer's disease models (2015)](https://pubmed.ncbi.nlm.nih.gov/25557367/). Mol Neurobiol. 2015;51(3):1040-1049.
[Zhang L, et al. Small molecule TrkB agonists for treating neurodegenerative diseases (2022)](https://pubmed.ncbi.nlm.nih.gov/35089012/). J Med Chem. 2022;65(2):1366-1385.
[Nagahama Y, et al. AAV-BDNF gene therapy for Parkinson's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33784456/). Mol Ther Methods Clin Dev. 2021;21:205-215.
[Wang J, et al. BDNF Val66Met polymorphism and brain function (2020)](https://pubmed.ncbi.nlm.nih.gov/33068391/). Brain Res Bull. 2020;163:141-152.
[Costa A, et al. TrkB signaling in neurogenesis and neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37098012/). Cell Stem Cell. 2023;30(5):589-604.
[Liu X, et al. 7,8-DHF: a promising TrkB agonist for neurodegenerative diseases (2023)](https://pubmed.ncbi.nlm.nih.gov/38010456/). Adv Sci. 2023;10(15):e2203456.Background
The study of NTRK2 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
See Also
- [BDNF Gene](/genes/bdnf)
- [NGF Gene](/genes/ngf)
- [NTRK1 Gene](/genes/ntrk1)
- [Neurotrophin Signaling Pathway](/mechanisms/neurotrophin-signaling)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Synaptic Plasticity Pathway](/mechanisms/synaptic-plasticity)
- [Neurotrophic Factor Therapy](/therapeutics/neurotrophic-factors)
- [TrkB Signaling](/proteins/trkb)
External Links
- [NCBI Gene: NTRK2](https://www.ncbi.nlm.nih.gov/gene/4915)
- [UniProt: Q16620](https://www.uniprot.org/uniprot/Q16620)
- [OMIM: NTRK2](https://www.omim.org/entry/600456)
- [BDNF and TrkB in Depression](https://www.nature.com/articles/nm.3830)
- [TrkB Agonists Clinical Trials](https://clinicaltrials.gov/ct2/results?term=TrkB+agonist)
Pathway Diagram
The following diagram shows the key molecular relationships involving NTRK2 Gene discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)